Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection

Competing Interest Statement

S.K.E, X.X.Z., and J.A.W. have filed a provisional patent on the described solution-based antibody detection assay (spLUC). J.E.G., A.A.G., I.L. and X.X.Z. have filed a provisional patent on the ACE2 variants.

Funding Statement

J.A.W. is grateful for funding from the Harry and Dianna Hind Endowed Professorship in Pharmaceutical Sciences and the Chan Zuckerberg Biohub that helped support this work. The National Science Foundation Graduate Research Fellowship Program supported S.K.E (1650113) and I.L (2017244707). Postdoctoral Fellowship support included a National Institutes of Health National Cancer Institute F32 (5F32CA239417 to J.R.B.), a Merck Fellow of the Damon Runyon Cancer Research Foundation (DRG-2297-17 to X.X.Z.), a Merck Postdoctoral Research Fellow from the Helen Hay Whitney Foundation (S.A.L.), and a National Institutes of Health K99/R00 (1K99GM135529 to A.A.G.). The LIINC cohort study was funded by NIH/NIAID 3R01AI141003-03S1 (T.J.H.). T.T.W was supported in part by Fast Grants, CEND COVID Catalyst Fund, the NIH/NIAID (U19AI111825 and R01AI139119) and by the Rockefeller University Center for Clinical and Translational Science Grant # UL1 TR001866. We would like to acknowledge funding from the Chan Zuckerberg Biohub, Rapid Response as well.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All patient samples were obtained using protocols approved by the UCSF, Stanford University, and Rockefeller University Institutional Review Boards and in accordance with the Declaration of Helsinki. Samples were de-identified prior to delivery to the lab where all assays described here were performed. Collection of remnant sera from Kaiser Permanente was approved by the Institutional Review Board of Stanford University (protocol #55718). Influenza virus vaccination samples were from a US cohort enrolled at the Rockefeller University Hospital in New York City in 2012-2013 under a protocol approved by the Institutional Review Board of Rockefeller University (protocol #TWA-0804). Samples from people with seasonal coronavirus infections were collected at the University of Chicago. Samples were de-identified serums of healthcare workers that had respiratory illnesses, were swabbed, and tested positive for common cold coronavirus infections in 2019 (U. Chicago protocol # 09-043-A).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes